Standout Papers

Phase 3 Trial of Semaglut... 2024 2026 2025 2024 40 80 120

Immediate Impact

21 hit
Sub-graph 1 of 11

Citing Papers

An overview of obesity‐related complications: The epidemiological evidence linking body weight and other markers of obesity to adverse health outcomes
2025 Hit
GLP-1-based therapies for diabetes, obesity and beyond
2025 Hit

Works of Iris Kliers being referenced

Semaglutide 2.4 mg in Participants With Metabolic Dysfunction‐Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial
2024 Hit

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Iris Kliers 113 110 60 42 35 14 278
Amin Xu 211 1.9× 44 0.4× 55 0.9× 19 0.5× 59 1.7× 16 311
Stella Hartono 71 0.6× 31 0.3× 29 0.5× 11 0.3× 44 1.3× 14 295
Li Xiao 92 0.8× 39 0.4× 61 1.0× 16 0.4× 127 3.6× 15 323
Marianthi Papagianni 161 1.4× 46 0.4× 49 0.8× 13 0.3× 25 0.7× 18 244
Joseph C. Ehrlich 50 0.4× 45 0.4× 122 2.0× 19 0.5× 62 1.8× 11 310
Huiying Liu 81 0.7× 20 0.2× 28 0.5× 16 0.4× 106 3.0× 13 297
Catarina Vale 109 1.0× 172 1.6× 42 0.7× 24 0.6× 58 1.7× 22 272
Madalena von Hafe 93 0.8× 160 1.5× 36 0.6× 22 0.5× 53 1.5× 19 243
Rie Ibusuki 108 1.0× 49 0.4× 26 0.4× 20 0.5× 45 1.3× 13 196
Magaly Alva 21 0.2× 26 0.2× 41 0.7× 25 0.6× 30 0.9× 10 262

All Works

Loading papers...

Rankless by CCL
2026